Scott Thorogood

Scott Thorogood

Chairman, CEO and Co-founder

Scott Thorogood is a serial CEO and entrepreneur with over 25 years of international senior management and turnaround experience, focused on life sciences, software, cybersecurity and other technology initiatives.

Thorogood is the cofounding Chairman and CEO of Nanovision Biosciences in La Jolla, CA. Nanovision has developed a breakthrough nano-scale retinal implant designed to restore sight to individuals blinded by retinal diseases such as macular degeneration. Its non-biological division is applying its image sensor technology based on a new physics discovery to low light imaging applications for DoD and commercial markets. In addition to Nanovision, Thorogood has co-founded several technology companies and served as board member and executive advisor for many other emerging growth ventures internationally, including as Chairman and founding CEO of Tradebeam (acquired by CDC /Aptean) and Oasis Inc (acquired by Sybase/SAP), as well as board observer and business advisor for Renova Therapeutics, a transformational biopharmaceutical company focused on a one-time gene therapy treatment for congestive heart failure (CHF) and type 2 diabetes. He also secured the founding investment required to launch the company. In addition, Thorogood served as executive business turnaround and technology advisor for the Canopy Group Board of Directors, a Utah based venture capital group with a large portfolio of technology companies.

Thorogood holds a BS in Mathematics and Psychology from the University of Alberta and serves as a virtual entrepreneur in residence for the Johnson Graduate School of Management at Cornell University.

William Freeman

William Freeman, MD

Medical Consultant and Co-founder

Gabriel A. Silva

Gabriel Silva, PhD

Neuroscience Advisor and Co-founder

Larry Murril

Larry Murrill

CFO

Sue Bauchner

Sue Bauchner, PhD, PMP

Director of Engineering

Partnership logos

In partnership with the University of California, San Diego.

Ready to learn more?

Our technology is singularly unique in how the sub retinal device tailors the electrical neural stimulation parameters to the individual patient. It is the most advanced technology available capable of achieving such a degree of patient specificity.

Contact Us